




ROLE OF -ADRENERGIC RECEPTORS IN THE  
ORAL ACTIVITY OF ZINC- 2-GLYCOPROTEIN (ZAG) 
 
Steven T. Russell and Michael J. Tisdale 
Nutritional Biomedicine, School of Life and Health Sciences, 
Aston University, Birmingham, B4 7ET, UK 
 
 
Running Title: Role of -AR in the oral activity of ZAG 
Abbreviations: ZAG, Zinc- 2-glycoprotein; 1-AR, 1-adrenergic receptor; 2-AR, 2-adrenergic 
receptor; 3-AR, 3-adrenergic receptor;  TNF-  Tumour necrosis Factor- ; UCP-1, uncoupling 






 Zinc- 2-glycoprotein (ZAG) is an adipokine with the potential as a therapeutic agent in the 
treatment of obesity and type 2diabetes..  In this study we show that human ZAG which is a 41kDa 
protein, when administered to ob/ob mice at 50 g day-1po in the drinking water produced a 
progressive loss of body weight (5g after 8 days treatment), together with a 0.5oC increase in rectal 
temperature, and a 40% reduction in urinary excretion of glucose. There was also a 33% reduction in 
the area under the curve during an oral glucose tolerance test and an increased sensitivity to insulin. 
These results were similar to those after iv administration of ZAG. However, tryptic digestion was 
shown to inactivate ZAG. There was no evidence of human ZAG in the serum, but a 2-fold elevation 
of murine ZAG, which was also observed in target tissues such as white adipose tissue. To determine 
whether the effect was due to interaction of the human ZAG with the -adrenoreceptor ( -AR) in 
the gastrointestinal tract before digestion, ZAG was co-administered to ob/ob mice together with 
propanolol (40mgkg-1), a non-specific -AR antagonist. The effect of ZAG on body weight, rectal 
temperature, urinary glucose excretion, improvement in glucose disposal and increased insulin 
sensitivity were attenuated by propanolol, as was the increase in murine ZAG in the serum. These 
results suggest that oral administration of ZAG increases serum levels through interaction with a -









 The increasing prevalence of obesity and the associated type 2 diabetes are a major health 
problem for the twenty first century. Current therapeutic agents are limited in efficacy, while 
treatment-associated adverse events have meant many agents being withdrawn. 
 We have previously investigated zinc- 2-glycoprotein (ZAG) as a treatment for obesity and 
type 2 diabetes (1). ZAG is a soluble protein of Mr41kDa, which resembles a class 1 major 
histocompatability complex (MHC) heavy chain, and has a major groove capable of binding 
hydrophobic molecules, that could be important in its action (2). ZAG was first identified as the lipid 
mobilising factor in cancer cachexia following its isolation from the cachexia-inducing MAC16 
tumour, and from the urine of cachectic patients (3). Treatment of either aged (4),or obese (1), mice 
with ZAG produced a time-dependent decrease in body weight through specific loss of carcass lipid, 
while there was an expansion of the non-fat carcass mass. ZAG is produced by a range of tissues 
including white (WAT) and brown (BAT) adipose tissue, liver, heart, lung and skeletal muscle, as well 
as certain tumours that induce cachexia (5). Expression of ZAG mRNA in adipose tissue is high in 
cancer cachexia, where lipid stores are low (5), and low in obesity, where lipid stores are high (6). 
Thus ZAG expression is negatively correlated with BMI and fat mass (6). ZAG expression is negatively 
regulated by tumour necrosis factor-  (TNF- ), and positively regulated by the PPAR  agonist 
rosiglitazone (7), 3-adrenergic receptor ( 3-AR) agonists (5) and glucocorticoids (8). ZAG also 
induces its own expression in adipose tissue through interaction with a 3-AR (8). In this way 
extracellular ZAG can induce expression of intracellular ZAG in target tissues, which has been 
suggested to be more important locally than circulating ZAG (6). 
 Previously studies have administration ZAG by either the i.p. (4), or i.v. (1) routes. However, 
neither route is convenient for clinical use. Here our study investigates the effect of ZAG on obesity 
and diabetes in the ob/ob mouse when administered by the oral route. This would not normally be 
considered to be ineffective for a protein molecule. However, the ability of ZAG to induce its own 
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expression through a 3-AR (8) enables the message to be transmitted from gastrointestinal tract to 





MATERIALS AND METHODS 
Materials 
 FCS (foetal calf serum) was from Biosera (Sussex, UK), while DMEM (Dulbecco’s modified 
Eagles Medium) was from PAA (Somerset, UK) and Feestyle medium was purchased from Invitrogen 
(Paisley, UK). Hybond A nitrocellulose membranes and peroxidise – conjugated rabbit anti-mouse 
antibody were from GE Healthcare (Bucks, UK), while enhanced chemiluminescene  (ECL) 
development kits were purchased from Thermo Scientific (Northumberland, UK). Mouse monoclonal 
antibodies to full-length human and mouse ZAG were from Santa Cruz Biotechnology (Santa Cruz, 
CA. A mouse insulin ELISA kit was purchased from DRG (Marburg, Germany) and glucose 
measurements in both urine and plasma were made using a Boots (Nottingham, UK)  glucose kit. L-
[U-14C] tyrosine (sp.act 16.7 GBqmmol-1) was purchased from Perkin Elmer Ltd, (Cambridge, UK), 
while 2-[1-14C] deoxy-D-glucose (sp.act 1.85GBqmmol-1) was from American Radiolabeled Chemicals 
(Cardiff, UK). 
 
Production and purification of ZAG 
 Recombinant human ZAG was produced by HEK293F cells transfected with pcDNA3.1 
containing human ZAG (1). Cells were grown for 2 weeks in Freestyle medium containing neomycin 
(50 gml-1) under an atmosphere of 5% CO2 in air. The cells were then removed by centrifugation 
(700g for 15min), 1litre of medium was concentrated to 1ml, and the ZAG was extracted by binding 
to activated DEAE cellulose, following by elution with 0.3M NaCl before washing and concentrating 
with sterile PBS. The ZAG produced was greater than 95% pure mainly due to ZAG’s negative charge, 
as determined by sodium dodecylsulphate polyacrylamide electrophoresis (SDS PAGE), and was free 
of endotoxin (1).For [14C] ZAG L-[U-14C] tyrosine was added to the media (1 Ciml-1), the cells were 
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allowed to grow for 2 weeks and ZAG was purified as above. The specific activity of the ZAG was 221 
Ci mol-1, and the purity of the product is shown in Fig 3A. 
Cyclic AMP determination 
 CHOK1 cells transfected with human 1-, 2- and 3-AR were maintained in DMEM 
supplemented with 2mM glutamine, hygromycin B (50 gml-1), G418 (200mgml-1) and 10% FCS, 
under an atmosphere of 10% CO2 in air. For cyclic AMP production cells were grown in 24-well plates 
in 1ml nutrient medium, and ZAG, after tryptic digestion as described in the legend to Fig. 3C, was 
incubated for 30min. The medium was then removed and 0.5ml of 20mM HEPES, pH7.5, 5mM EDTA 
and 0.1mM isobutylmethylxanthine was added, followed by heating on a water bath for 5min, and 
cooling on ice for 10min. The concentration of cyclic AMP was determined using a Parameter cyclic 
AMP assay kit (New England Biolabs, Hitchin, Herts, UK). 
Animals 
 Obese (ob/ob) mice (average weight 65g) were bred in our own colony, and were kept in an 
air conditioned room at 22+2oC with ad libitum feeding of a rat and mouse breeding diet (Special 
Diet Services, Witham, UK) and tap water. These animals exhibit a more severe form of diabetes 
then C57BL/6J ob/ob mice, and the origins and characteristics of the Aston ob/ob mouse has been 
previously described (9). Animals were grouped (n=5) to receive either ZAG/PBS (50 g day-1), or PBS 
in their drinking water, the experiment was repeated three times after a power analysis was 
performed. Each mouse consumed 5ml day-1 water, and this did not change on ZAG administration 
(1). The ZAG was replaced every 48h. One group of mice receiving ZAG were also administered 
propanolol (40mgkg-1, p.o.) daily. The dose of ZAG was chosen to be the same as that previously 
administered i.v. (1), so that a direct comparison could be made, between the two routes. Body 
weight, food and water intake, urinary glucose excretion, and body temperature, determined by the 
use of a rectal thermometer (RS Components, Northants, UK), were measured daily. A glucose 
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tolerance test was performed on day 3. Animals were fasted for 12h, followed by oral administration 
of glucose (1gkg-1 in a volume of 100 l by gavage). Blood samples were removed from the tail vein at 
15, 30, 60 and 120 min and used for the measurement of glucose. Urinary glucose was measured by 
collecting 0.5ml urine and testing glucose concentration using a Boots glucose monitor. After 8 days 
of treatment the animals were terminated by cervical dislocation, tissues were removed and rapidly 
frozen in liquid nitrogen, and maintained at -80oC. Future work would be to repeat this work in diet-
induced animals as alternative to a model with gene alteration, although previous studies have 
shown the ob/ob mouse to be a good indicator of potential human treatments (9).Animal studies 
were conducted under Home Office Licence according to the UKCCCR Guidelines for the care and 
use of laboratory animals. 
Glucose uptake into adipocytes 
 Single cell suspensions of white and brown adipocytes were obtained by incubation of 
minced epididymal subcutaneous and visceral WAT and BAT for 2 and 2.5h, respectively, with Krebs-
Ringer bicarbonate (KRBB) containing 1.5mgml-1 collagenase and 4% BSA under 95% oxygen-5% CO2 
at 37oC. Adipocytes were washed twice in 1ml KRBB, pH7.2, and then incubated for 10min at room 
temperature in 0.5ml KRBB, containing 18.5MBq 2-[1-14C] deoxy-D-glucose (2-DG), together with 
non-radioactive 2-DG, to give a final concentration of 0.1mM, in the absence or presence of insulin 
(10nM). Uptake was terminated by addition of 1ml ice-cold KRBB without glucose. Adipocytes were 
washed three times with 1ml KRBB and lysed by the addition of 0.5ml 1M NaOH. The uptake of 2-[1-
14C] DG was determined by liquid scintillation counting. 
Glucose uptake into soleus muscle 
 The uptake of 2-[1-14C] DG into freshly isolated soleus muscles in the absence and presence 




Western blotting analysis 
 Tissues were thawed, washed in PBS and lysed in PhosphosafeTM Extraction reagent for 5min 
at room temperature, followed by sonication at 4oC. Cytosolic protein (5-20ug) formed by 
centrifugation at 18,000g for 5min at 4oC, was resolved on 12% SDS PAGE by electrophoresis at 180V 
for about 1h.  To determine ZAG in serum 30 l samples containing 20 g total protein were 
electrophoresed as above. Protein was transferred to 0.45 m nitrocellulose membranes, which had 
been blocked with 5% (w/v) non-fat dried milk (Marvel) in Tris-buffered saline, pH 7.5, at 4oC 
overnight. Membranes were washed for 15min in 0.1%Tween 20 buffered saline prior to adding the 
primary antibodies. Both primary and secondary antibodies were used at a dilution of 1:1000. 
Incubation was for 1h at room temperature, and development was by ECL. Blots were scanned by a 
densitometer to quantify differences. 
PCR 
Total RNA was extracted from tissues (50–120 mg) and adipocytes with Trizol. RNA samples used for 
real-time PCR were treated with a DNA-free kit (Ambion) to remove any genomic DNA. The RNA 
concentrationwas determined from the absorbance at 260 nM. 1 g of total RNA of each sample 
was reverse transcribed to cDNA in a final volume of 20 l by using a Reverse-iT first strand kit 
(ABgene). 1 l of each cDNA sample was then amplified in a PCR mixture containing 0.02 mM of each 
primer and 1.1·Reddy Mix PCR Master Mix(ABgene) in a final volume of 25 l. Human b-actin was 
used as a housekeeping gene. The primer pair used and the PCR cycling conditions were as follows. 
Mouse ZAG 5’-GCCTTCTTCCACTACAACAG-3’ (forward), 5’-TTCAGGACACTCCTCCTCTA-3’ (reverse); 
annealing temperature (TA) 54 _C; 33 cycles. Mouse -actin: 5’-GTGGCATCCACGAAACTACCTT-3’ 
(forward), 5’-GGACTCGTCATACTCCTGCTTG-3’ (reverse) (antisense); TA 57 oC; 23 cycles. PCR was 
performed on a thermal cycler (Hybaid) with an initial denaturation at 94 oC for 2 min followed by 
cycles consisting of denaturation at 94 oC for 20 s, annealing at the specified temperature for 25s, 
and extension at 72 oC for 59 s; the final step was an extension at 72oC for 5 min. PCR products were 
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separated on a 1% agarose gel stained with ethidium bromide. The PCR products were sequenced 
commercially to confirm their identity (MWG Biotech). (7) 
 
RT-PCR 
Relative ZAG mRNA levels were quantified using real-time PCR with an ABI Prism 7700 Sequence 
Detector (Applied Biosystems). Mouse -actin mRNA levels were similarly measured and served as 
the reference gene. Primers and Taqman probes were designed using PrimerExpress software 
(Applied Biosystems). The sequences of primers and Taqman probes were as follows. 
Mouse ZAG: 5’-GAGCCTGTGGGACCTTGGA-3’ (forward), 5’-CCTCCCTGGCCCTCTGAA-3’ (reverse), and 
5’-FAM-AATGGAGGACTGGGAGAAGGAAAGCCAG-TAMRA-3’; Mouse -actin5’-
ACGGCCAGGTCATCACTATTG-3’ (forward),5’-CAAGAAGGAAGGCTGGAAAAGA-3’ (reverse), and 5’-
FAM-ACGAGCGGTTCCGATGCCCTG-TAMRA-3’.Amplification was performed in a 96-well plate using a 
master mix made from qPCR core kit (Eurogentec), with 300 nM forward(900 nM in the case of -
actin) and 900 nM reverse primers, 225 nM probe and 1 l of cDNA in a final volume of 25 l. Each 
sample was run in triplicate for ZAG and in duplicate for -actin. The PCR parameters were as 
follows: initial2 min at 50 oC, denaturation at 95 oC for 10 min followed by 40cycles of denaturation 
at 95 oC for 15 s and combined annealing and extension at 60 oC for 1 min. Data were recorded and 
analysed with Sequence Detector software (Applied Biosystems). ZAG mRNA levels were normalized 




 Results are shown as mean +SEM for at least three replicate experiments. Differences in 
means between groups were determined by one-way analysis of variance (ANOVA) followed by 




Previous studies (1) have shown that animals treated with iv ZAG consume the same amount 
of food and water as PBS controls. It was therefore convenient for oral administration to dissolve the 
ZAG in drinking water, since this would avoid the stress associated with dosing by gavage. The 
concentration of ZAG in the drinking water was such that the animals would consume 50 g per day, 
so that a direct comparison could be made with the iv route (1). The effect of oral ZAG on the body 
weight of ob/ob mice is shown in Fig. 1A. After 5 days of treatment the difference in body weight 
between the ZAG and PBS groups was 3.5g, which was the same as that found after i.v. 
administration (1), while after 8 days of treatment there was 5g weight difference between the 
groups. As with i.v. administration of ZAG (1) there was an increase in rectal temperature, which 
became significant after 4 days of treatment (Fig. 1B), while there was a 40% reduction in urinary 
glucose excretion, which became significant after 1 day of treatment (Fig. 1C). This suggests that the 
oral ZAG also reduced the severity of diabetes in the ob/ob mouse. A glucose tolerance test, 
performed on animals after 3 days of oral ZAG, showed a reduced peak blood glucose concentration, 
and a 33% reduction in the total area under the curve (AUC) during the entire glucose tolerance test 
in ZAG treated animals (Fig. 2A). ZAG also decreased the insulin response to the glucose challenge 
(Fig. 2B) although a direct comparison has not been made. These results suggest that oral 
administration of ZAG is as effective in inducing weight loss, and reducing the severity of diabetes in 
ob/ob mice as when given by the i.v. route (1).To determine whether this effect was due to 
interaction with a -AR, ZAG was administered orally to ob/ob mice that were co-administered the 
non-specific -AR antagonist propanolol (40mg/kg). As shown in Fig. 2C while mice administered 
ZAG orally lost weight this was blocked with propanolol, which had no effect on weight gain of mice, 
administered PBS. Initially propanolol was administered at 20mgkg-1, but this did not prevent the 
weight loss with ZAG so the dose was increased to 40mgkg-1 Antagonists of 1- and 2-AR are known 
to be less effective against 3-AR responses. Propanolol also completely attenuated the ZAG induced 
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increase in rectal temperature (Fig. 2D) and the reduction in urinary excretion of glucose (Fig. 2E). 
Propanolol also blocked the reduced peak blood glucose concentration in the glucose tolerance test 
(Fig. 2F) and the increase in insulin sensitivity (Fig. 2G). Propanolol also completely attenuated the 
decrease in serum glucose and insulin levels after ZAG administration to ob/ob mice. The elevation 
of serum glycerol level, suggesting that it blocked lipolysis induced by ZAG, along with the decrease 
in serum triglycerides and non-esterified fatty acids (Table 1). 
 One possibility by which this could occur is that ZAG escapes digestion by proteolytic 
enzymes, and is absorbed directly into the blood stream. To investigate this ZAG was biosynthetically 
labelled with L-[U-14C] tyrosine. SDS/PAGE showed that the purified product contained a single band 
of radioactivity of Mr43kDa (Fig. 3A). The [14C] ZAG was then administered to ob/ob mice by the oral 
route. SDS PAGE of serum proteins provided no evidence for intact ZAG (Fig. 3A). Western blotting of 
serum using mouse monoclonal antibody to full-length human ZAG, confirmed the absence of 
human ZAG (Fig.  3B). Another possibility is that a tryptic digest of ZAG could mediate the effect, but 
there is no evidence for absorption of peptides into the blood stream (Fig. 3A). Alternatively a 
peptide could act within the gastrointestinal tract. The effect of ZAG has been shown to be 
manifested through interaction with a 3-AR (10). However, treatment of CHO cells transfected with 
human 1-, 2 or 3-AR with a tryptic digest of ZAG had no effect on cyclic AMP production (Fig. 3C), 
while intact ZAG stimulated cyclic AMP production in cells with 2- and 3-AR. This suggests that 
interaction with trypsin in the stomach would inactivate ZAG. Therefore ZAG must act before it 
reaches the stomach. 
 Previous studies (8) have shown that ZAG can induce its own expression through interaction 
with a 3-AR. and may be able to induce its own expression through interaction with 3-AR in the 
oesophagus before being digested in the stomach and other parts of the gastrointestinal tract. Since 
there was an absence of human ZAG in the serum of orally dosed mice (Fig. 3B). Western blotting of 
serum from mice dosed orally with ZAG for 8 days showed a two-fold (P<0.001) increased level of 
12 
 
murine ZAG (Fig. 4A). The specificity of the antibodies against human ZAG is shown in Fig. 4B. Thus 
the anti-mouse ZAG antibody did not detect human ZAG. Therefore the human ZAG administered 
orally has resulted in an increase in mouse ZAG in the serum, and this has also caused a two fold rise 
of mouse ZAG in WAT (P<0.001) (Fig. 4C). Administration of propanolol also attenuated the oral 
route ZAG-induced stimulation of glucose uptake ex vivo into epididymal, subcutaneous and visceral 
adipocytes in the absence and presence of insulin (Fig. 5A), It also attenuated glucose uptake into 
BAT in the absence and presence of insulin (Fig. 5B), and glucose uptake ex vivo into gastrocnemius 
muscle in the presence of insulin (Fig. 5C). In addition there was no increase in murine ZAG in the 
serum (Fig. 5D), and no evidence of human ZAG (Fig. 3B) in animals co-administered propanolol. 
These results suggest that oral administration of ZAG increases circulatory levels by interaction with 
a -AR, probably in the oesophagus, since ZAG mRNA appears to be dramatically increased in 
oesophageal tissue compared to that of the stomach, small intestine or the colon and is on par with 
that seen in the liver in mice treated with ZAG orally (Fig 6A and B). Gene expression for ZAG in the 








 Previous studies (11) have shown ZAG to bind to a high affinity binding site on the 3-AR, 
with a Kd value of 78+45nM and Bmax of 282+1 fmole mg protein-1. Many of the effects of ZAG are 
also found with 3-AR agonists, including an increased lipid mobilization and reduction of body fat 
(11), an increase of rectal temperature and induction of UCP1 in BAT (11), normalization of 
hyperglycaemia and hyperinsulinaemia, improvement in glucose tolerance and reduction of the 
insulin response during a glucose tolerance test (12), and also attenuation of muscle wasting (17). 
The 3-AR is found predominantly on adipocytes (14), but has also been reported on BAT and 
prostate (15) as well as in the smooth muscle of the gastrointestinal tract in a variety of species, and 
mediates relaxation in the ileum, gastric fundus, jejunum, colon and oesophagus (16, 17, 18) ). This 
study has shown that the previously described presence of a -AR in the gastrointestinal tract, 
coupled with the ability of ZAG to induce its own expression through a -AR (8) enables ZAG to be 
administered orally and this stimulus to be converted into circulating ZAG. The -AR responsive to 
oral ZAG must be in the mouth or oesophagus, since tryptic digestion of ZAG produced a product 
with no stimulation of the -AR.  Using RT.PCR analysis of ZAG mRNA this study shows a large 
increase in the oephagus of animals receiving ZAG orally. The lack of expression of ZAG in the lower 
part of the gastrointestinal tract, despite the reported presence of -AR (16, 17, 18) would support 
the contention that ZAG is digested in the stomach. Previous studies have suggested that a tryptic 
digest of a cancer lipolytic factor called toxohormone L still retains biological activity (19). The 
mechanism by which the ZAG signal is transmitted from the gastrointestinal tract to the general 
circulation has been elucidated by administration of human ZAG to a mouse, and depends on the 
specificities of the antibodies to human and murine ZAG. As expected human ZAG is digested, but 
murine ZAG appears in the serum and responsive tissue such as WAT.  This effect is mediated 
through a -AR, since mice treated with the non-specific -AR antagonist, propanolol, showed no 
murine ZAG in their serum, and the effects of ZAG on body weight, lipolysis and glucose disposal 
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were completely attenuated. Previous studies (20) have shown that the lipolytic effect of ZAG in 
vitro was also completely attenuated by propanolol. We did not use agents that have been reported 
to be specific for 3-AR, such as SR59230A (21), since our previous studies have indicated that this 
antagonist also attenuates activation through both the 1 and 2-ARwhile other investigators (22, 
23) have shown it to be an antagonist of the 1-AR). SR59230A has also been seen to bind to 
albumin when used in vivo (21). The specific -AR involved can only be determined using specific -
AR “knock-out” animals. The ability of propanolol to attenuate the reduction in body weight, 
increase in temperature, reduction in blood glucose, insulin, NEFA, and triglycerides, increase in 
serum glucose, disposal of glucose and increased insulin sensitivity induced by ZAG in ob/ob mice 
suggests that these effects are mediated through a -AR. 
 The effects of orally administered human ZAG at a dose of 50 g day-1 are almost identical to 
those found when human ZAG was administered by the i.v. route (1), suggesting a quantitative 
transfer of the message from human ZAG into the serum as mouse ZAG. ZAG is unusual in inducing 
its own expression, and the mechanism is unknown apart from a requirement of the 3-AR (8). The 
3-AR agonist BRL37344 has also been shown to increase levels of ZAG mRNA in 3T3 L1 adipocytes, 
suggesting a common mechanism. The cyclic AMP formed from interaction with a 3-AR would lead 
to activation of protein kinase A (PKA), the C-subunits of which are capable of passively diffusing into 
nucleus, where they can regulate gene expression through direct phosphorylation of cyclic AMP 
response element binding protein (CREB) (24). 
 Plasma ZAG protein has been shown to be decreased in ob/ob mice (25) and a similar 
decrease has been reported in high fat diet-fed mice (26). Serum ZAG levels have also been found to 
be low in obese human subjects (26, 27). Most of the serum ZAG is thought to come from adipose 
tissue and liver, and expression levels of ZAG mRNA in these tissues in ob/ob mice have been shown 
to be significantly reduced (25). This is at least partly due to the pro-inflammatory cytokine tumour 
necrosis factor- (TNF- ), (25) which is elevated in adipose tissue of obese subjects (28). Many of 
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the effects of obesity may be due to this low expression of ZAG, because of its function in regulating 
lipid metabolism (1), and ZAG’s ability to increase expression of 3-AR in gastrocnemius muscle, BAT 
and WAT (unpublished results), which are low in obesity (29). The ability of ZAG to increase serum 
levels when administered by the oral route provides a mechanism for countering some of the effects 
of obesity. It also raises the possibility of some uncooked foods such as broccoli, rich in ZAG 





This work has been supported by Halsa Pharmaceuticals, TX, USA. 
Disclosure Summary: S.T.R. and M.J.T. received grant support June 1, 2008 to August 2011 from 
Halsa Pharmaceuticals.  
Address all correspondence and requests for reprints to Dr Steven T. Russell (LHS, Aston University, 




1. Russell ST, Tisdale MJ. Antidiabetic properties of zinc- 2-glycoprotein in ob/ob mice. 
Endocrinol 151: 948-957, 2010. 
2. Delker SL, West Jr AP, McDermott L, Kennedy MW, Bjorkman PJ. Crystallographic studies of 
ligand binding by zinc- 2-glycoprotein. J Structural Biol 148: 205-213, 2004. 
3. Todorov PT, McDevitt TM, Meyer DJ, Ueyama DJ, Ohkubo I, Tisdale MJ. Purification and 
characterisation of a tumor lipid-mobilizing factor. Cancer Res 58: 2353-2358, 1998. 
4. Russell ST, Zimmerman TP, Domin BA, Tisdale MJ. Induction of lipolysis in vitro and loss of 
body fat in vivo by zinc- 2-glycoprotein. Biochim Biophys Acta 1636: 59-68, 2004. 
5. Bing C, Bao Y, Jenkins J, Sanders P, Manieri M, Cinti S, Tisdale MJ, Trayhurn P. Zinc- 2-
glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice 
with cancer cachexia. Proc Natl Acad Sci USA 101:2500-2505, 2004. 
6. Mracek T, Ding Q, Tzanavari T, Kos K, Pinkney J, Wilding J, Trayhurn P, Bing C. The adipokine 
zinc- 2-glycoprotein is downregulated with fat mass expansion in obesity. Clin Endocrinol 
72: 334-341, 2010. 
7. Bao Y, Bing C, Hunter L, Jenkins JR, Wabitsch M, Trayhurn P. Zinc- 2-glycoprotein , a lipid 
mobilizing factor, is expressed and secreted by human (SGBS) adipocytes. FEBS Lett 579:47-
47, 2005. 
8. Russell ST, Tisdale MJ. The role of glucocorticoids in the induction of zinc- 2-glycoprotein 
expression in adipose tissue in cancer cachexia. Br J Cancer 92: 876-881, 2005. 
9. Bailey CJ, Flatt PR, Atkins TW. Influence of genetic background and age on the expression of 
the obsese hyperglycaemic syndrome in Aston ob/ob mice. Int J Obese 6: 11-21, 1982. 
10. Russell ST, Hirai K, Tisdale MJ. Role of 3-adrenergic receptors in the action of a tumour lipid 
mobilizing factor. Br J Cancer 86: 424-428, 2002. 
17 
 
11. Inokuma K, Okamatsu-Ogura Y, Omachi A, Matsushita Y, Kimura K, Yamashita H, Saito M. 
Indispensible role of mitochondrial UCP1 for antiobesity effect of 3-adrenergic stimulation. 
Am J Physiol Endocrinol Metab 290:E1014-E1021, 2006. 
12. Liu X, Perusse F, Bukowiecki LJ. Mechanism of the antidiabetic effects of the 3-adrenergic 
agonist CL-316243 in obese Zucker-ZDF rats. Am J Physiol Regulatory Intergrative Comp 
Physiol 43:R1212-R1219, 1998. 
13. Lynch GS, Ryall JG. Role of -adrenoceptor signalling in skeletal muscle: Implications for 
muscle wasting and disease. Physiol Rev 88:729-767, 2008. 
14. Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, Strosberg 
AD. Molecular characterisation of the human 3-adrenergic receptor. Science 245: 1118-
1121, 1989. 
15. Krief S, Lonnqvist F, Raimbault S, Baude B, Van Spronsen A, Arner P. Strosberg AD, Ricquier 
D, Emorine LJ. Tissue distribution of 3-sdrenergic receptor mRNA in man. J Clin Invet  91: 
344-349, 1993. 
16. Manara L, Croci T, Landi M. Beta(3)-adrenegic receptors and intestinal motility. Fund Clin 
Pharmacol 9: 332-342, 1995. 
17. Fletcher DS, Candelore MR, Grujic D, Lowell BB, Luell S, Susulic VS, Macintyre DE. Beta-3 
adrenergic receptor antagonists cause an increase in gastrointestinal transit time in wild-
type mice, but not in mice lacking the beta3-adrenergic receptor. JPET 287: 720-724, 1998. 
18. Sarma DNK, Banwait K, Basak A, Dimarino AJ, Rattan S. Inhibitory effect of 3-adrenoceptor 
agonist in lower esophageal sphincter smooth muscle: In vitro studies. JPET 304:48-55, 2003. 
19. Masuno H. Yamasaki N, Okuda H. Purification and characterisation of a lipolytic factor 
(Toxohormone-L) from cell-free fluid of ascites sarcoma 180. Cancer Res 41:284-288, 1981. 
20. Khan S, Tisdale MJ. Catabolism of adipose tissue by a tumour-producing  lipid-mobilising 




21. Nisoli E, Tonello C, Landi M, Carruba MO. Functional studies of the first selective 3-
adrenergic receptor antagonist SR59230A in rat brown adipocytes. Mol. Pharmacol 49:7-14, 
1996. 
 
22. Leblais V, Pourgeaud F, Doloeres PM, Ivorra D, Guilbert C, Marthan R, Muller B. Role of a-
adrenergic receptors in the effect of the -adrenegic receptor ligands CGP 12177, Bupranolol 
and SR59230A, on the contraction of rat intrapulmonary artery. J Pharmacol Exp Ther 309: 
137-145. 
23. Bexis S, Docherty JR. Role of 1- and 3-adrenoceptors in the modulation of SR59230A of 
the effects of MDMA on body temperature in the mouse. Br J Pharmacol 158: 259-266, 
2009. 
24. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor 
CREB. Nat Rev Mol Cell Biol 2: 599-609, 2001. 
25. Mracek T, Gao D, Tzanavari T, Bao Y, Xiao X, Stocker C, Trayhurn P, Bing C. Downregulation 
of zinc- 2-glycoprotein in adipose tissue and liver of ob/ob mice and by tumour necrosis 
factor-  in adipocytes. J Endocrinol 204: 165-172, 2010. 
26. Gong FY, Zhang SJ, Ding JY, Zhu HJ, Pan H, Li NS, Shi YF. Zinc- 2-glycoprotein is involved in 
regulation of body weight through inhibition of lipogenic enzymes in adipose tissue. Int J 
Obes 33: 1023-1030, 2009. 
27. Selva DM, Lecube A, Hernandez C, Baena JA, Fort JM, Simo R. Lower zinc- 2-glycoprotein 
production by adipose tissue and liver in obese patients unrelated to insulin resistance. J Clin 
Endocrinol Metab 94:4499-4507, 2009. 
28. Yudkin JS, Stehouwer CD, Emesis JJ, Coppack SW. C-reactive protein in healthy subjects: 
associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for 
19 
 
cytokines originating from adipose tissue? Arteriosclerosis, Thrombosis, and Vascular Biol 
19: 972-978, 1999. 
29. Robidoux J, Martin TL, Collins S. Beta-adrenergic receptors and regulation of energy 







Fig. 1 Effect of human ZAG on body weight (A), rectal temperature (B) and urinary glucose excretion 
(C) in ob/ob mice. ZAG was dissolved in the drinking water so that animals consumed 50 gday-
1 (), while a control group received an equal volume of PBS () (0.5ml in 5ml water). 
Differences from PBS controls are shown as ***, p<0.001.  
Fig. 2 Effect of oral human ZAG () compared with PBS () on glucose and insulin tolerance of ob/ob 
mice after 3 days of treatment. Animals were fasted for 12h before oral administration of 
glucose (1gkg-1 in a volume of 100 l). Blood samples were removed from the tail vein at the 
time intervals shown and used for the measurement of serum glucose (A) and insulin (B). The 
inset in (A) shows the total area under the glucose curves (AUC) in arbitrary units. Differences 
from PBS controls are shown as ***, p<0.001.  Effect of propranolol (40mgkg-1, po, daily) on 
ZAG-induced reductions in obesity and diabetes in ob/ob mice. Animals received ZAG (50 g 
daily) in their drinking water as described in the legend to Fig 1, either alone (), or in the 
presence of propranolol (), while a control group received PBS (). Changes in body weight 
(C), rectal temperature (D), and urinary glucose excretion (E) were monitored over a 8 day 
period.  A glucose tolerance test (F), with measurement of serum insulin levels (G) was made 3 
days after starting the oral ZAG. Differences from PBS controls are shown as ***, p<0.001, 
while differences from ZAG alone are shown as #, p<0.001. 
Fig. 3 (A) SDS/PAGE of purified biosynthetically labelled [14C] ZAG (15 g) and serum from ob/ob mice 
administered [14C] ZAG (50 g; 212 Ci mol-1) orally for 24h. (B) Western blot of serum from 
ob/ob mice administered non-radioactive ZAG for 8 days in the absence or presence of 
propanolol (40mg kg-1) using anti-human ZAG monoclonal antibody. (C) Effect of a tryptic 
digest of ZAG in comparison with intact ZAG on cyclic AMP production by CHO cells 
transfected with human 1-AR (), 2-AR()and 3-AR (   ) after 30min incubation. ZAG 
(1mg) was incubated with trypsin (200 g) in 1ml 10mM Tris.HCl, pH8 for 4h at 37oC and 
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proteolysis was terminated by addition of the trypsin inhibitor (200 g). High molecular weight 
material was removed by a Sephadex G25 column followed by dialysis using an Amicon 
filtration cell containing a 10kDa cut-off membrane filter. 
Fig. 4 Western blots of ZAG. (A) Expression of murine ZAG in serum of ob/ob mice administered 
human ZAG or PBS orally for 8 days as shown in Fig. 1. Each lane is a sample from an individual 
mouse. The blot was probed with anti-mouse ZAG antibody. (B) Human ZAG was 
electrophoretically blotted, and probed with antibodies specific to human and mouse ZAG. (C) 
Expression of ZAG in WAT quantitated using an anti-mouse ZAG antibody after 8 days 
treatment with human ZAG Differences from PBS treated animals are shown as ***, p<0.001.  
 
 Fig. 5 Effect of propanolol on the stimulation of glucose uptake into WAT, BAT and skeletal muscle 
of ob/ob mice ex vivo after administration of ZAG. (A) Glucose uptake into epididymal (ep), 
subcutaneous (sc) and visceral (vis) adipocytes from animals treated with PBS and ZAG with or 
without propanolol (Prop) for 8 days in the absence (closed bars), or presence (open bars) of 
insulin (10nM). (B) Glucose uptake into brown adipocytes from mice treated with PBS, ZAG or 
ZAG+propanolol for 8 days with or without insulin (10nM). (C) Glucose uptake into isolated 
gastrocnemius muscle of ob/ob mice administered either PBS or ZAG with or without 
propanolol for 8 days. (D) Qantitation of serum ZAG in mice treated with PBS, ZAG or ZAG+ 
propanolol for 3 days by immunoblotting using an anti-mouse ZAG monoclonal antibody. Each 
lane represents serum form an individual mouse. Differences from PBS treated animals are 
shown as *, p<0.05 or ***, P<0.001, while differences from ZAG treated animals are shown as 
##, p<0.001. 
Fig 6  ZAG gene expression in mouse tissues examined by RT-PCR. (A) Tissue specificity of expression 
from mice treated with ZAG orally (B) ZAG expression in control mice. (C) ZAG mRNA 
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expression in mouse tissue after either oral administration of ZAG (    ) or PBS (□). Differences 
from PBS treated animals are shown as ***, P<0.001. 
